Zhejiang Jingxin Pharmaceutical
800 East Xinchang Avenue, Yulin Street, Xinchang, Zhejiang Province, 312500, China
Overview
Up to now, the company has a registered capital of 725 million yuan, total assets of 5.3 billion yuan and net assets of 3.6 billion yuan. The company has more than 2,900 employees, including more than 230 masters.The company has two headquarters in Xinchang and Hangzhou. It has six production sites including the plant in Xinchang for finished medicines, the two API plants in Shangyu and Shangrao, the TCM production site in Bayannaoer, Inner Mongolia, and the medical equipment production base of Shenzhen and Shenyang. Aside from that, the company also owns a breeding base in Yunnan. In Shanghai, the company has established its own research institute i n the Zhangjiang Hi-Tech Park. Joint ventures and collaberated labs have also been founded over the years in the U.S.A., the U.K., Denmark, Isereal, Korea as well as other countries.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Medical Device
- Pharmaceutical
Investment portfolio
- Mapi Pharma
Led · Equity · Nov 2018
Mapi Pharma is a clinical-stage, fully integrated biopharmaceutical company developing high barrier-to-entry, high added-value lifecycle management (LCM) pharmaceuticals and complex active pharmaceutical ingredients (APIs) and formulations. Its lead product is a Glatiramer Acetate (Copaxone®) Depot long-acting injection administered once every four weeks, which is in final preparations for a phase III clinical trial. The company plans to expand its pipeline to additional 505(b)(2) and Depot innovative and QQ products beyond the GA Depot. Mapi is built on chemical and pharmaceutical R&D capabilities, with R&D facilities in Israel and China and an API production facility in the Neot-Hovav Eco Industrial Park in Israel. The company holds a strong IP position and has filed numerous patent applications for APIs and formulations. The recent equity investment will support Mapi’s future development and pipeline expansion. Mapi Pharma Ltd. is a clinical-stage biopharmaceutical company developing long-acting depot injections for multiple sclerosis. Its lead product, Glatiramer Acetate (Copaxone®) Depot (GA Depot), is a once-every-four-weeks intramuscular injection and a life‑cycle management (LCM) formulation of Copaxone®. The company recently completed a Phase II open-label, two-arm, multicenter study evaluating safety, tolerability, and efficacy of once-a-month 80mg or 40mg GA in relapsing-remitting MS patients. Mapi received $10m in funding from aMoon Fund to support development and enable initiation of a Phase III trial for GA Depot. Led by Chairman and CEO Ehud Marom, the company focuses on LCM products and complex generics and intends to advance additional depot long-acting injections in its pipeline. Mapi maintains R&D facilities in Israel and China and an API production facility in the Neot-Hovav Eco Industrial Park south of Beersheba, Israel. Mapi Pharma is a development-stage pharmaceutical company based in Ness Ziona, Israel. It is developing the GA Depot, a once-every-four-weeks glatiramer acetate injection for the treatment of multiple sclerosis. The GA Depot was in Phase II at the time of the report. The company intends to use the funds to advance the product to the initiation of the single pivotal Phase III trial needed for registration. The company is led by chairman and CEO Ehud Marom. The recent financing was announced to support progression of the GA Depot clinical program.
Team
No current team members are available.